You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

MenB disease occurs throughout the world and is endemic in Europe and Latin America 3

  • IMD remains a rare disease in Europe; in 2012, the overall notification rate for confirmed IMD cases was 0.68 per 100 000, ranging from 0.11 to 11.76. Serogroup B was responsible for 68% of confirmed meningococcal infections. 1 Serogroup B was observed in all countries that reported on serogroup. 1
  • MenB is the most important cause of endemic meningitis in industrialized countries, accounting for 30% to 40% of the cases in North America and for up to 80% in some European countries. MenB also can cause severe, persistent epidemics, which begin slowly but may persist for 10 years or longer, as seen in the past in Norway; in Cuba, Brazil and areas of Chile; and currently in New Zealand. 2
  • In Europe, MenB is the leading cause of infant bacterial meningitis and sepsis. This serogroup is also responsible for prolonged outbreaks of disease in Latin America, the Pacific Northwest of the USA, Canada and Australasia. 3
  • The highest notification rate for serogroup B IMD in 2012 was observed in cases < 1 year of age, followed by cases between one and four years of age. Often a smaller peak is reported in adolescents and young adults (15-25y). 1

*Contributing countries: Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom

Complications of MenB 4

According to a control case study performed in the UK between 2008 and 2010:

  • Most children survive serogroup B meningococcal disease without major sequelae, however approximately 10%-20% of children who survive MenB IMD experience major complications, including major amputations (i.e., limb loss), seizures, major hearing loss and intellectual disability. 4 5
  • More than one-third of survivors of childhood MenB disease experience other lifelong deficits, such as psychological disorders, borderline IQ (IQ<85), digit amputations, minor or unilateral hearing loss (i.e. in one ear) and minor communication deficits. 4

References:

  1. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, 2012. Stockholm: ECDC; 2015. http://ecdc.europa.eu/en/publications/Publications/Surveillance%20of%20IBD%20in%20Europe%202012.pdf Last accessed December 2016 
  2. World Health Organisation, NUVI, 2012, http://apps.who.int/nuvi/meningitis/en/ Last accessed December 2016
  3. Watson PS, Turner DP, Clinical experience with the meningococcal B vaccine, Bexsero: Prospects for reducing the burden of meningococcal serogroup B disease, Vaccine 2016;34(7):875-880
  4. Viner RM, et al., Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study Lancet Neurol. 2012;11(19):774-783
  5. World Health Organization (WHO). Meningococcal meningitis fact sheet No. 141, 2015. Available at: http://www.who.int/mediacentre/factsheets/fs141/en Last accessed December 2016

Prescription Only Medicine.
Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health http://www.phs.moh.gov.cy/web/guest/drug-search

Trade marks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.